Are the antidepressant effects of insulin-sensitizing medications related to improvements in metabolic markers?

Abstract

Insulin-sensitizing medications were originally used in psychiatric practice to treat weight gain and other metabolic side effects that accompany the use of mood stabilizers, antipsychotics, and some antidepressants. However, in recent studies these medications have been shown to cause improvement in depressive symptoms, creating a potential new indication outside of metabolic regulation. However, it is still unclear whether the antidepressant properties of these medications are associated with improvements in metabolic markers. We performed a systematic search of the literature following PRISMA guidelines of studies investigating antidepressant effects of insulin-sensitizing medications. We specifically focused on whether any improvements in depressive symptoms were connected to the improvement of metabolic dysfunction. Majority of the studies included in this review reported significant improvement in depressive symptoms following treatment with insulin-sensitizing medications. Nine out of the fifteen included studies assessed for a correlation between improvement in symptoms and changes in metabolic markers and only two of the nine studies found such association, with effect sizes ranging from R2 = 0.26–0.38. The metabolic variables, which correlated with improvements in depressive symptoms included oral glucose tolerance test, fasting plasma glucose and glycosylated hemoglobin following treatment with pioglitazone or metformin. The use of insulin-sensitizing medications has a clear positive impact on depressive symptoms. However, it seems that the symptom improvement may be unrelated to improvement in metabolic markers or weight. It is unclear which additional mechanisms play a role in the observed clinical improvement. Some alternative options include inflammatory, neuroinflammatory changes, improvements in cognitive functioning or brain structure. Future studies of insulin-sensitizing medications should measure metabolic markers and study the links between changes in metabolic markers and changes in depression. Additionally, it is important to use novel outcomes in these studies, such as changes in cognitive functioning and to investigate not only acute, but also prophylactic treatment effects.

Effects of weight loss intervention on anxiety, depression and quality of life in women with severe obesity and polycystic ovary syndrome

“…Moreover, brain insulin resistance has been shown to alter dopamine turnover and induce anxiety- and depressive-like behaviors in mice 39 . Insulin-sensitizing medications have been used in psychiatric practice to treat weight gain and other metabolic side effects that accompany the use of some antidepressant SSRI drugs 40 . Interestingly, recent studies show that metformin and glitazones can cause improvement in mental health 40 – 42 .…”

Integrating Metabolomics and Network Pharmacology to Explore the Mechanism of Xiao-Yao-San in the Treatment of Inflammatory Response in CUMS Mice

“…It has been demonstrated to inhibit the expression of TNF-α, IL-6, and IL-1β in monocytes. PPARG exerts negative regulation on the transcription of inflammation-responsive genes by antagonizing the activator protein-1 and NF-kB signaling pathways [35]. Therefore, the inflammatory response triggered by stress can potentially result in a compensatory reduction in PPARG levels within the body.…”

Higher serum chromium level may be associated with the presentation of depression in patients with metabolic dysfunction-associated fatty liver disease: evidence from NHANES survey

“…IR is a predictor of non-response to some antidepressants, it seems to be a state-marker of clinical or subclinical depression, moreover, some insulin-sensitizing interventions are beneficial for the treatment of major depressive disorder ( 18 ). Furthermore, a systematic review investigated the antidepressant effects of insulin-sensitizing medications and found that the use of insulin-sensitizing medications had a positive impact on depressive symptoms ( 19 ).…”